Retatrutide 15mg

Description

A potent 15mg triple agonist peptide (GLP-1, GIP, and GCG) designed for advanced metabolic and endocrine research applications.

Retatrutide 15mg is a triple agonist peptide currently at the forefront of metabolic research. This synthetic molecule targets three distinct receptors: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. By acting as a multi-receptor agonist, Retatrutide is studied for its synergistic effects on metabolic homeostasis and its unique ability to influence multiple hormonal pathways simultaneously. In laboratory settings, this compound is utilised to investigate the physiological interactions between incretin hormones and glucagon. Researchers focus on how the concurrent stimulation of these receptors affects lipid metabolism, glucose regulation, and energy expenditure in animal models. The inclusion of the glucagon receptor agonism distinguishes Retatrutide from earlier dual-agonist research compounds, providing a more complex mechanism for scientific observation.

Product Overview

Retatrutide (RT) is a synthetic peptide consisting of 39 amino acids. It belongs to the class of multi-receptor agonists, specifically designed to engage the GIP, GLP-1, and glucagon receptors. This 15mg presentation is provided in a highly stable format to ensure the integrity of the peptide chain during laboratory experimentation. Research indicates that the triple-agonism approach may offer a more comprehensive understanding of metabolic signaling compared to mono or dual-receptor ligands.

Specifications

Form: Lyophilised Powder Quantity: 15mg Purity: ≥99% (verified by HPLC) Storage: Store in a cool, dry place, away from direct light. Long-term storage should be maintained at -20°C.

Research Applications

Research into Retatrutide is primarily focused on chronic metabolic conditions and energy balance. Current studies explore its role in augmenting thermogenesis through glucagon receptor activation, while maintaining glucose sensitivity via GIP and GLP-1 pathways. It is an essential tool for laboratories investigating the next generation of peptide-based interventions for metabolic dysfunction and fatty acid oxidation.

Research Use Notice

For laboratory research use only. Not for human or veterinary use.